UBS Group’s Medtronic MDT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $556M | Buy |
6,412,252
+2,241,365
| +54% | +$215M | 0.08% | 245 |
|
|
2025
Q4 | $401M | Sell |
4,170,887
-7,031,991
| -63% | -$683M | 0.07% | 287 |
|
|
2025
Q3 | $1.07B | Buy |
11,202,878
+5,489,720
| +96% | +$505M | 0.17% | 99 |
|
|
2025
Q2 | $498M | Buy |
5,713,158
+662,193
| +13% | +$56.2M | 0.09% | 224 |
|
|
2025
Q1 | $454M | Buy |
5,050,965
+139,334
| +3% | +$12.5M | 0.08% | 234 |
|
|
2024
Q4 | $392M | Buy |
4,911,631
+734,267
| +18% | +$63.6M | 0.07% | 256 |
|
|
2024
Q3 | $376M | Sell |
4,177,364
-114,678
| -3% | -$9.65M | 0.08% | 236 |
|
|
2024
Q2 | $338M | Buy |
4,292,042
+196,723
| +5% | +$16.1M | 0.08% | 227 |
|
|
2024
Q1 | $357M | Buy |
4,095,319
+340,060
| +9% | +$29M | 0.09% | 223 |
|
|
2023
Q4 | $309M | Sell |
3,755,259
-261,945
| -7% | -$20M | 0.09% | 218 |
|
|
2023
Q3 | $315M | Sell |
4,017,204
-465,003
| -10% | -$38.9M | 0.11% | 184 |
|
|
2023
Q2 | $395M | Sell |
4,482,207
-2,247,951
| -33% | -$194M | 0.13% | 153 |
|
|
2023
Q1 | $543M | Sell |
6,730,158
-313,008
| -4% | -$25.5M | 0.2% | 105 |
|
|
2022
Q4 | $547M | Sell |
7,043,166
-985,567
| -12% | -$79.9M | 0.2% | 102 |
|
|
2022
Q3 | $648M | Sell |
8,028,733
-1,046,445
| -12% | -$94M | 0.28% | 70 |
|
|
2022
Q2 | $814M | Sell |
9,075,178
-174,779
| -2% | -$17.7M | 0.33% | 61 |
|
|
2022
Q1 | $1.03B | Sell |
9,249,957
-935,077
| -9% | -$98.8M | 0.34% | 57 |
|
|
2021
Q4 | $1.05B | Sell |
10,185,034
-287,195
| -3% | -$33.3M | 0.3% | 61 |
|
|
2021
Q3 | $1.31B | Sell |
10,472,229
-521,364
| -5% | -$67.5M | 0.41% | 36 |
|
|
2021
Q2 | $1.36B | Sell |
10,993,593
-208,770
| -2% | -$26.2M | 0.44% | 34 |
|
|
2021
Q1 | $1.32B | Sell |
11,202,363
-1,176,359
| -10% | -$138M | 0.44% | 34 |
|
|
2020
Q4 | $1.45B | Buy |
12,378,722
+235,981
| +2% | +$26M | 0.49% | 29 |
|
|
2020
Q3 | $1.26B | Sell |
12,142,741
-544,601
| -4% | -$54.7M | 0.48% | 37 |
|
|
2020
Q2 | $1.16B | Sell |
12,687,342
-954,661
| -7% | -$91.5M | 0.49% | 36 |
|
|
2020
Q1 | $1.23B | Sell |
13,642,003
-1,299,517
| -9% | -$138M | 0.58% | 27 |
|
|
2019
Q4 | $1.7B | Sell |
14,941,520
-632,521
| -4% | -$69.4M | 0.59% | 24 |
|
|
2019
Q3 | $1.69B | Sell |
15,574,041
-1,110,758
| -7% | -$116M | 0.65% | 21 |
|
|
2019
Q2 | $1.62B | Buy |
16,684,799
+1,677,045
| +11% | +$153M | 0.63% | 24 |
|
|
2019
Q1 | $1.37B | Buy |
15,007,754
+34,173
| +0.2% | +$3.06M | 0.56% | 28 |
|
|
2018
Q4 | $1.36B | Sell |
14,973,581
-176,250
| -1% | -$16.5M | 0.62% | 22 |
|
|
2018
Q3 | $1.49B | Buy |
15,149,831
+330,542
| +2% | +$30.6M | 0.59% | 20 |
|
|
2018
Q2 | $1.27B | Sell |
14,819,289
-44,851
| -0.3% | -$3.75M | 0.55% | 24 |
|
|
2018
Q1 | $1.19B | Buy |
14,864,140
+1,076,594
| +8% | +$88.8M | 0.51% | 27 |
|
|
2017
Q4 | $1.11B | Buy |
13,787,546
+1,050,215
| +8% | +$84.1M | 0.46% | 28 |
|
|
2017
Q3 | $991M | Buy |
12,737,331
+992,008
| +8% | +$82.4M | 0.46% | 27 |
|
|
2017
Q2 | $1.04B | Buy |
11,745,323
+851,050
| +8% | +$71.8M | 0.54% | 21 |
|
|
2017
Q1 | $878M | Buy |
10,894,273
+1,032,236
| +10% | +$80.6M | 0.48% | 30 |
|
|
2016
Q4 | $702M | Sell |
9,862,037
-216,166
| -2% | -$17M | 0.39% | 40 |
|
|
2016
Q3 | $871M | Buy |
10,078,203
+62,059
| +0.6% | +$5.41M | 0.52% | 23 |
|
|
2016
Q2 | $869M | Buy |
10,016,144
+603,567
| +6% | +$48.8M | 0.55% | 18 |
|
|
2016
Q1 | $706M | Buy |
9,412,577
+434,344
| +5% | +$32.7M | 0.47% | 25 |
|
|
2015
Q4 | $691M | Buy |
8,978,233
+405,194
| +5% | +$30.5M | 0.45% | 26 |
|
|
2015
Q3 | $574M | Buy |
8,573,039
+225,537
| +3% | +$16.6M | 0.41% | 31 |
|
|
2015
Q2 | $619M | Buy |
8,347,502
+155,287
| +2% | +$11.9M | 0.41% | 28 |
|
|
2015
Q1 | $639M | Sell |
8,192,215
-265,059
| -3% | -$20.1M | 0.44% | 30 |
|
|
2014
Q4 | $611M | Buy |
+8,457,274
| New | +$587M | 0.43% | 31 |
|
Other funds holding MDT
VCM
VPM
UBS Group's MDT Position: Q1 2026 in Review
UBS Group increased its Medtronic (MDT) stake by 54% in Q1 2026, buying an estimated $215M and bringing the position to 6,412,252 shares worth $556M. The position accounts for 0.08% of the portfolio, ranked #245.
UBS Group first reported a position in MDT in Q4 2014 and has held it in 46 quarters since. The position peaked at $1.7B in Q4 2019. 2,231 funds tracked by Wall St. Rank hold MDT as of Q1 2026.
- UBS Group held 6,412,252 shares of Medtronic worth $556M as of Q1 2026.
- UBS Group bought 2,241,365 Medtronic shares in Q1 2026, an estimated $215M.
- Medtronic made up 0.08% of UBS Group's portfolio in Q1 2026, its #245 holding.
- UBS Group first reported a position in Medtronic in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Medtronic position peaked at $1.7B in Q4 2019.
- 2,231 funds tracked by Wall St. Rank held Medtronic as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.